Podcast - OSO BioPharmaceuticals Kimberly K. Ray
Kimberly K. Ray
Sr. Manager, Project Management,
With an increasing focus on containment for pharmaceutical manufacturing, active pharmaceutical ingredients (APIs) are becoming more targeted, hence more potent. Environmental, health and safety (EHS) groups push for the use of engineering controls, but the implementation of RABS and isolation technology may be an ideal solution for some pharmaceutical manufacturers; however it may not be the most efficient processing option, or the most cost effective. A risk-based approach to containment offers some alternatives. We will discuss how Oso BioPharmaceuticals has successfully implemented scientific, risk-based approach to handling hazardous compounds, how it has impacted their clients, and the reaction of regulatory bodies. OsoBio will share how implementation of this approach has affected its business as well as its processes.